Cambridge Vision Technology (CVT) is dedicated to revolutionizing the early detection of dementia, including Alzheimer’s disease, through scientifically validated diagnostic tests based on established biomarkers
Our mission is to provide innovative solutions that facilitate early intervention, improving patient outcomes and quality of life.
Early detection of dementia and AD
There is a significant unmet need for cost-effective, non-invasive, and scalable screening solutions for Dementia and Alzheimer’s Disease (AD) risk. Current diagnostic methods often detect the disease too late, are highly invasive, and fail to identify all types of dementia. CVT addresses this gap by focusing on detecting dementia in its Mild Cognitive Impairment (MCI) stage and earliest pathological stages, before clinical symptoms are evident.
This early detection of dementia is crucial, as the latest treatments are preventative rather than restorative, making timely diagnosis essential for effective intervention. Our approach targets biomarkers in the human retina, an extension of the central nervous system and brain, providing a unique and effective means of early detection of dementia.
Our Technology
CVT’s technology leverages ocular biomarkers to identify characteristics of Mild Cognitive Impairment (MCI), dementia, and Alzheimer’s disease pathology. By analysing these biomarkers, we can stratify patients along the Dementia/Alzheimer’s disease continuum, indicating the likelihood that a patient is currently in the early stages of dementia and their potential progression to more advanced stages. This stratification enables tailored interventions and monitoring, enhancing the precision of treatment plans and improving patient outcomes.
Roadmap for early detection of dementia
Looking ahead, CVT aims to expand its capabilities to identify and stratify various dementia sub-types, such as vascular dementia and frontotemporal dementia. Our goal is to enable timely diagnosis and intervention, ensuring that patients receive the most appropriate care based on their specific condition.
By continuously advancing our technology and broadening our diagnostic scope, we strive to make a significant impact on the lives of those affected by dementia and Alzheimer’s disease.
